Clinical Trial Update: Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety and immunogenicity of an aluminium hydroxide/LHD153R adjuvanted Meningococcal C-CRM197 conjugate vaccine; completed with posted r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infections Meningococcal
• Meningococcal Infection

Drugs mentioned

• Aluminium Hydroxide/LHD153R adjuvanted Meningococcal C-CRM197 conjugate vaccine

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Meningococcal | Phase 1 | Status: COMPLETED | Results posted: 2019-06-07